Marisa Wexler, MS,  senior science writer—

Adding more lines of treatment may reduce the risk of rehospitalization among adults with pulmonary arterial hypertension (PAH) who are taking only one medication, a study reports. “Our results suggest that a shift away from monotherapy towards a greater reliance on combination therapy might help to reduce the risk…

People with pulmonary arterial hypertension (PAH) have abnormalities in their gut microbes that may play a role in their disease, a study reports. Transplanting gut microbes from healthy rats into the digestive tract of a rat model of PAH led to a reduction in disease severity, suggesting that targeting…

Soon after Yutrepia (treprostinil) was approved by the U.S. Food and Drug Administration (FDA) to treat some forms of pulmonary hypertension, the therapy’s maker, Liquidia, scheduled its first commercial shipment to specialty pharmacies. “We have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the…

Plans for a Phase 2b clinical trial that will test CS1, Cereno Scientific‘s experimental treatment for pulmonary arterial hypertension (PAH), have been endorsed by the U.S. Food and Drug Administration (FDA). The FDA’s endorsement comes just a few weeks after a meeting between Cereno and the FDA…

Most people with pulmonary arterial hypertension (PAH) who were treated with Uptravi (selexipag) and followed up for 10 years in an extension study are still alive, according to new data. Adding two other types of PAH therapy or starting triple therapy within six months of a diagnosis…

The first participant has been dosed in a Phase 2 trial testing the experimental oral therapy mirivadelgat in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Phase 2 trial, called WINDWARD (NCT06475781), aims to enroll about 126 adults with PH-ILD, ages 18 to 85. Participants will…

Synhale Therapeutics has acquired the rights to the experimental therapy telaglenastat (CB-839), which has previously been tested as a potential cancer therapy. The company is planning to launch a Phase 2 clinical trial to test telaglenastat in people with pulmonary hypertension (PH). “This acquisition represents a unique opportunity to…

The PAH Initiative is hosting a video event in May to provide information about the benefits of exercise for people with pulmonary arterial hypertension (PAH). “The Power of Movement: Cardiopulmonary Rehabilitation for PAH” is part of the initiative’s PAH Today national broadcast series. Lana Melendres-Groves, MD, director of…

The advocacy organization Phaware is launching a series of podcasts to explore new advances in the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The series will be launched as part of “I’m Aware That I’m Rare: the phaware podcast,” which can be found online…

Treatment with the approved therapy Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with pulmonary arterial hypertension (PAH), according to results from the Phase 3 ZENITH clinical trial. Findings were published in The New England Journal of Medicine, in the study, “…

The U.S. Food and Drug Administration (FDA) is poised to soon issue a final determination on Yutrepia, an inhaled dry powder formulation of treprostinil, up for approval to treat both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The FDA granted Yutrepia…

People with coarctation of aorta, or COA — a condition marked by narrowing where the body’s largest blood vessel connects to the heart — are at high risk of developing pulmonary hypertension (PH), and this risk increases as time goes on, a study showed. The data also showed that…